Copyright
©2011 Baishideng Publishing Group Co.
World J Diabetes. Feb 15, 2011; 2(2): 19-23
Published online Feb 15, 2011. doi: 10.4239/wjd.v2.i2.19
Published online Feb 15, 2011. doi: 10.4239/wjd.v2.i2.19
Drug | Mechanism of action | Effect on weight | Side effects |
Phentermine | Reducing food intake: sympathomimetic amine | 3.6 kg at 6 mo | Headache, insomnia, irritability, palpitations and nervousness |
Diethylpropion | As above | 3.0 kg at 6 mo | As above |
Fluoxetine | Reducing food intake: selective serotonin reuptake inhibitor | 4.74 kg at 6 mo, and 3.15 kg at 1 year | Agitation and nervousness |
Sibutramine | Reducing food intake: combined norepinephrine and serotonin reuptake inhibitor | 4.45 kg at 1 year | Headache, insomnia, dry mouth and constipation. Long term treatment increases the risk of major adverse cardiovascular events |
Orlistat | Reducing fat absorption: lipase inhibitor | 2.59 kg at 6 mo and 2.89 kg at 1 year | Diarrhoea, flatulence, bloating, abdominal pain and dyspepsia |
Rimonabant | Reducing food intake: selective CB1 receptor blocker | 5.1 kg at 1 year | Nausea, dizziness, arthralgia and diarrhoea |
- Citation: Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011; 2(2): 19-23
- URL: https://www.wjgnet.com/1948-9358/full/v2/i2/19.htm
- DOI: https://dx.doi.org/10.4239/wjd.v2.i2.19